The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1660
October 3, 2022
View Complete Issue         Table of Contents 2019 
Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo
October 3, 2022 (Issue: 1660)
The 1.5% cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib (Opzelura – Incyte) has been approved by the FDA for topical treatment of nonsegmental vitiligo (NSV) in patients ≥12 years old. Opzelura is the first product to be...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo
Article code: 1660b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.